Vaxart narrows reverse split range to max 1-for-20; proposes proportional authorized share reduction

Vaxart, Inc.

Board narrowed proposed reverse split range: no ratio higher than 1-for-20.
If reverse split passes, authorized shares will be proportionally reduced at a future stockholder meeting.
Company urges stockholders to vote 'FOR' Proposal #2 by May 20, 2025, to avoid Nasdaq delisting.
Leading proxy advisors ISS and Glass Lewis support Proposal #2.
Proxy supplement filed; board cites stockholder input as reason for amendments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.